Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES 简体中文 中文 हिन्दी HI
Sign Up
Log in
Astellas Pharma Inc banner

Astellas Pharma Inc
SWB:YPH

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
SWB:YPH
Watchlist
Price: 12.4 EUR -2.36% Market Closed
Market Cap: €34.9B
Write Note Create Alert

Intrinsic Value

Is YPH undervalued or overvalued?

See the intrinsic value estimate for Astellas Pharma Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

YPH Intrinsic Value
LOCKED
Unlock
Today vs. history

YPH looks undervalued.
But is it cheap by its own standards?

See how today’s valuation compares with YPH’s past valuations and how the stock performed after similar periods.

See what happened next Free account required
Monitor YPH
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value
Get notified when the price drops into your buy zone
Intrinsic Value Locked
Current Price €12.4
Margin of Safety 20% Locked
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to YPH

Fundamental Analysis

What Astellas Pharma Does

Pharmaceuticals Health Care

Astellas Pharma is a Japanese drug company that discovers, develops, makes, and sells prescription medicines. Its main products treat areas such as urology, transplant medicine, immunology, cancer, and eye disease. The company spends heavily on research and then brings branded drugs through testing, approval, manufacturing, and distribution.

Headquarters
Japan JP
Employees
13 643
IPO date
May 16, 1949
Read the full company overview
View Company Overview

Astellas Pharma has no economic moat

No Moat Narrow Wide

Patent protection keeps copies of individual Astellas medicines out temporarily, but does not provide lasting protection across the business. Generic competition has reduced Myrbetriq sales, while competing treatments give doctors alternatives to medicines such as Xtandi.

Read the full moat analysis
Financials
Efficiency

Earnings Waterfall
Astellas Pharma Inc

Wall St Price Targets

Capital Returns

Buyback Yield
LOCKED
Debt Paydown Yield
LOCKED

Competitive Landscape

Continue YPH Research

Summary
YPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
YPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YPH stock valuation using valuation multiples.
Wall St Estimates
YPH price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financial Statements
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financial Statements
Discount Rate
Other Astellas Pharma Inc listings:
OTC • USD
ALPMY
 OTC • USD
ALPMF
 F • EUR
YPH
 TSE • JPY
4503
 F • EUR
YPHA
 XMUN • EUR
YPH
 DUS • EUR
YPH
Discover More
What is the Intrinsic Value of one YPH stock?

The intrinsic value for Astellas Pharma Inc (YPH) under the Base Case is hidden EUR.

Is YPH stock undervalued or overvalued?

Compared with the current market price of 12.4 EUR, the stock appears hidden.

Back to Top
ALPHA SPREAD
Follow us
Join 363,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.